| Adams, Kirkwood F |
| Completed | 3 | 240 | US | Dapagliflozin 10 MG, sodium-glucose cotransporter-2(SGLT2) inhibitors, Protocolized Diuretic Therapy | Vanderbilt University Medical Center, AstraZeneca | Heart Failure, Diabetes Mellitus, Type 2 | 05/23 | 05/23 | | |
NCT05592275: A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF) |
|
|
| Active, not recruiting | 2 | 456 | Europe, Canada, Japan, US, RoW | LY3540378, Placebo | Eli Lilly and Company | Heart Failure, Heart Failure With Preserved Ejection Fraction | 01/25 | 01/25 | | |
NCT04840914: A Study of LY3461767 in Participants With Chronic Heart Failure With Reduced Ejection Fraction |
|
|
| Completed | 1 | 44 | Japan, US | LY3461767, Placebo | Eli Lilly and Company | Chronic Heart Failure With Reduced Ejection Fraction | 05/24 | 05/24 | | |
| Guerrero-Miranda, Cesar Y |
NCT05592275: A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF) |
|
|
| Active, not recruiting | 2 | 456 | Europe, Canada, Japan, US, RoW | LY3540378, Placebo | Eli Lilly and Company | Heart Failure, Heart Failure With Preserved Ejection Fraction | 01/25 | 01/25 | | |
| Reddy, Yogesh |
NCT06409026: Sotatercept on Central Cardiopulmonary Performance and Peripheral Oxygen Transport During Exercise in Pulmonary Arterial Hypertension |
|
|
| Recruiting | 4 | 21 | US | Sotatercept | Mayo Clinic | Pulmonary Arterial Hypertension | 02/25 | 02/25 | | |
NCT05564637: A Study of Treprostinil to Treat Interstitial Lung Disease Pulmonary Hypertension |
|
|
| Enrolling by invitation | 2 | 24 | US | Treprostinil, Right Heart Catheterization (RHC) while exercising, Optional Muscle Biopsy | Mayo Clinic, United Therapeutics | Pulmonary Arterial Hypertension, Interstitial Lung Disease, Healthy Adults | 01/25 | 01/25 | | |
NCT06036914: A Study of Ultra High Dose Diuretics to Treat Heart Failure |
|
|
| Completed | 2 | 20 | US | Bumetanide, Ultra-high dose diuretic, Furosemide, Standard dose diuretic | Mayo Clinic | Heart Failure; With Decompensation | 10/24 | 10/24 | | |
NCT05592275: A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF) |
|
|
| Active, not recruiting | 2 | 456 | Europe, Canada, Japan, US, RoW | LY3540378, Placebo | Eli Lilly and Company | Heart Failure, Heart Failure With Preserved Ejection Fraction | 01/25 | 01/25 | | |
NCT04787445: Effects of Pulmonary Hypertension Therapy in Atypical Pulmonary Arterial Hypertension |
|
|
| Completed | N/A | 19 | US | | Mayo Clinic | Pulmonary Arterial Hypertension | 11/23 | 11/23 | | |
NCT05008432: Sleep Apnea in Heart Failure With Preserved Ejection Fraction |
|
|
| Completed | N/A | 48 | US | Home sleep apnea testing | Mayo Clinic, Itamar-Medical, Israel, Sleep Number Corporation | Heart Failure, Obstructive Sleep Apnea | 07/24 | 07/24 | | |
NCT05045079: Rhythm Control and Potential Early Surgery for Tricuspid Regurgitation |
|
|
| Completed | N/A | 4 | US | Inferior Vena Caval (IVC) Occlusion maneuver | Mayo Clinic | Severe Tricuspid Valve Regurgitation (Disorder) | 08/23 | 08/23 | | |
NCT05968859: A Study of Pulmonary Hypertension Peripheral Limitations |
|
|
| Recruiting | N/A | 40 | US | Aerobic Training, Leg Training | Mayo Clinic, National Heart, Lung, and Blood Institute (NHLBI) | Pulmonary Arterial Hypertension, Healthy | 07/28 | 07/28 | | |
| Park, Jean |
TRANSCEND-T2D-2, NCT06260722: Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor |
|
|
| Recruiting | 3 | 1250 | Canada, US, RoW | Retatrutide, LY3437943, Semaglutide | Eli Lilly and Company | Diabetes Mellitus, Type 2 | 12/26 | 03/27 | | |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
QWINT-2, NCT05362058: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time |
|
|
| Completed | 3 | 928 | Europe, Canada, Japan, US, RoW | Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec | Eli Lilly and Company | Diabetes, Type 2 Diabetes | 04/24 | 04/24 | | |
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) |
|
|
| Recruiting | 3 | 10000 | Europe, Canada, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD) | 02/29 | 02/29 | | |
QWINT-5, NCT05463744: A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy |
|
|
| Completed | 3 | 692 | Europe, Japan, US, RoW | Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec | Eli Lilly and Company | Type 1 Diabetes, Diabetes | 05/24 | 05/24 | | |
ATTAIN-1, NCT05869903: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities |
|
|
| Active, not recruiting | 3 | 3000 | Europe, Japan, US, RoW | Orforglipron, LY3502970, Placebo | Eli Lilly and Company | Obesity, Overweight, Overweight or Obesity | 07/25 | 07/27 | | |
| Active, not recruiting | 3 | 9541 | Europe, Canada, Japan, US, RoW | Obicetrapib, Placebo | NewAmsterdam Pharma, Monash University | Atherosclerotic Cardiovascular Disease | 11/26 | 11/26 | | |
ZONE, NCT05762107: A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes |
|
|
| Recruiting | 2 | 186 | Canada, US | Placebo, ZT-01, 7 mg, ZT-01, 15 mg, ZT-01, 22 mg | Zucara Therapeutics Inc. | Type 1 Diabetes Mellitus with Hypoglycemia | 06/25 | 07/25 | | |
NCT05343065: A Continuous Glucose Monitor Based Insulin Bolus Calculator (CGM-IBC) Study B |
|
|
| Completed | N/A | 27 | US | BlueStar 10 | Welldoc | Diabetes Mellitus | 12/22 | 12/22 | | |
| Recruiting | N/A | 264 | US | RESET Liner, RESET Sleeve, Duodenal-jejunal Bypass Liner (DJBL), EndoBarrier, Sham | Morphic Medical Inc., Biostatistical Consulting, Inc. | Diabetes type2, Obesity | 12/25 | 12/26 | | |
NCT05238142: In-Home Study with MiniMed™ 780G Pump Automated Control in Type 2-Evaluation of the AHCL System in Adults with Insulin-requiring Type 2 Diabetes |
|
|
| Active, not recruiting | N/A | 575 | US | MiniMed™ 780G Insulin Pump system | Medtronic Diabetes | Type 2 Diabetes Treated with Insulin | 01/25 | 02/25 | | |
| Wahid, Faisal |
CHANGE AFIB, NCT05130268: Early Dronedarone Versus Usual Care to Improve Outcomes in Persons With Newly Diagnosed Atrial Fibrillation |
|
|
| Completed | 4 | 339 | US | Dronedarone, Multaq | American Heart Association, Duke Clinical Research Institute, Sanofi | Atrial Fibrillation | 01/24 | 06/24 | | |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
| Active, not recruiting | 3 | 15374 | Europe, Canada, Japan, US, RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Obesity, Overweight | 10/27 | 10/27 | | |
NCT05592275: A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF) |
|
|
| Active, not recruiting | 2 | 456 | Europe, Canada, Japan, US, RoW | LY3540378, Placebo | Eli Lilly and Company | Heart Failure, Heart Failure With Preserved Ejection Fraction | 01/25 | 01/25 | | |
